Business · 01/04/2026Updated: 10/16/2026 · 1 min read
FDA Awards Priority Review Voucher to Sponsor of Rare Pediatric Disease Product YUVIWEL
Summary
The FDA has awarded a priority review voucher to Ascendis Pharma Growth Disorders (A/S) for its rare pediatric disease product YUVIWEL (navepegritide), approved on February 27, 2026.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →